Research from Water Tower Research, Water Tower Research

Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Research from Water Tower Research

Equity Research Firm

Equity Bottom-Up

<ul><li>AbbVie goes all in for Gilgamesh’s lead depression drug candidate.</li><li>On August 25, AbbVie (NYSE: ABBV) announced that it will acquire outright Gilgamesh’s lead novel pipeline drug program, bretisilocin, targeting the treatment of major depressive disorder (MDD) for up to $1.2 billion, inclusive of an upfront payment (yet to be disclosed) and development milestones.</li><li>This builds on a collaboration and option-to-license agreement established by the two parties last year whereby AbbVie paid Gilgamesh an upfront payment of $65 million, with an option to license future assets with potential milestone payments of up to $1.95 billion as well as tiered royalties from mid-single to low double digits on net sales should these developments move to commercialization. </li></ul>

AbbVie goes all in for Gilgamesh’s lead depression drug candidate.On August 25, AbbVie (NYSE: ABBV) announced that it will acquire outright Gilgamesh’s lead novel pipeline drug program, bretisilocin, targeting the treatment of major depressive disorder (MDD) for up to $1.2 billion, inclusive of an upfront payment (yet to be disclosed) and development milestones.This builds on a collaboration and option-to-license agreement established by the two parties last year whereby AbbVie paid Gilgamesh an upfront payment of $65 million, with an option to license future assets with potential milestone payments of up to $1.95 billion as well as tiered royalties from mid-single to low double digits on net sales should these developments move to commercialization. 

Cybin, Inc: AbbVie's Gilgamesh Transaction Sheds More Light on CYB003's Value